Bringing the total raised for the current class of 4Catalyzer companies to a quarter-billion dollars GUILFORD, Conn. –Feb. 2, 2016– LAM Therapeutics closed a $40 million financing to accelerate the development of therapeutics for the treatment of rare diseases and cancer. LAM Therapeutics is a 4Catalyzer company. 4Catalyzer is Connecticut’s premier biotechnology startup incubator and […]
LAM Therapeutics develops drugs for rare diseases and cancer. LAM takes advantage of the inflection point in biological understanding and computer science, leveraging big data from Next Gen sequencing, genome editing, chemical genomics, and combinational drug screening, to develop precision therapeutics and companion diagnostics. LAM has advanced two drugs into the clinic: LAM-001 for lymphangioleiomyomatosis, and LAM-002 for B-cell non-Hodgkin lymphoma.
LAM-001, inhaled mTOR kinase Inhibitor
Hyperactivation of mTOR signaling is a central driver in the genetic-based disease lymphangioleiomyomatosis . LAM Therapeutics is currently conducting a Phase 1 trial of its inhaled mTOR inhibitor developed to treat lymphangioleimyomatosis.
LAM-002, kinase inhibitor
LAM-002 is an exquisitely selective first-in-class kinase inhibitor that is cytotoxic for specific cancers with little to no effect on normal cells. LAM Therapeutics advanced LAM-002 into a Phase 1 trial in relapsed or refractory B-cell non-Hodgkin lymphoma within one year of discovery.
LAM-002 is also being evaluated in pre-clinical models of neurological disease.
LAM Therapeutics is actively applying its technologies to advance discovery of clinical stage drugs for immuno-oncology and rare disease indications.
LAM Therapeutics leverages Next Gen sequencing, advances in genome editing, computer science and artificial intelligence to discover and develop medicines faster, with more precision and at a lower cost than conventional approaches.
LAM Therapeutics applies its technologies to a unique comprehensive library of clinical stage drugs, thus enabling the rapid clinical development of potent, highly selective compounds that target specific drivers of human disease.
LAM Therapeutics is a fully-funded startup dedicated to developing breakthrough therapeutics for the treatment of rare diseases and cancer.
Working with proprietary technologies, LAM Therapeutics is making a difference. The company is privately funded, allowing you to focus 100% on doing the best science of your life.
Join a world-class team in developing the next-generation of breakthrough drugs. LAM Therapeutics is seeking extraordinary gifted and driven scientists, with a track record of success developing, implementing and scaling up new technologies.
Application process: Please, submit your CV along with a cover letter to email@example.com.
NOTES TO RECRUITERS
The Company does not accept resumes submitted by, or candidates referred from, external agencies by any means (including but not limited to via the Internet, email, fax, U.S. mail and/or verbal communications). Any third-party resume forwarded by such recruiters will be treated as a direct application and shall be deemed to be the property of the Company, and the Company reserves the right to contact the candidate directly and the recruiter will not receive any compensation from the Company.
Company is first to focus on developing drugs for Lymphangioleiomyomatosis Guilford, CT – June 6, 2013 – LAM Therapeutics, the first biopharmaceutical company dedicated to identifying and developing drugs for the treatment of Lymphangioleiomyomatosis (LAM), announced today that it has closed a Series A financing with private investors to launch operations. Proceeds from the financing will […]